In short
Clinical trials are studying HUMAN IGG1 HEXAVALENT ANTIBODY AGAINST TNFRSF4 in people with head and neck squamous cell carcinoma. These studies aim to see whether adding it to standard treatment can improve outcomes such as response, time without disease worsening, and survival. The main target group is adults with first-line recurrent or metastatic disease and high PD-L1 CPS.
Key points
- Clinical trials of HUMAN IGG1 HEXAVALENT ANTIBODY AGAINST TNFRSF4 are studying first-line treatment for head and neck squamous cell carcinoma. The main trial in the source data is an interventional randomized study in recurrent or metastatic disease with PD-L1 CPS of 20 or higher. It compares HUMAN IGG1 HEXAVALENT ANTIBODY AGAINST TNFRSF4 plus pembrolizumab against pembrolizumab with placebo. The study is authorised and plans to enroll 410 participants. Researchers are measuring overall response rate, progression-free survival, and overall survival. The trial data show a focus on whether adding the study drug can improve cancer control and survival.
Trial overview
The source data describe one interventional trial, which means researchers assign the study treatments and follow what happens over time. The study is titled “Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN),” and the condition studied is head and neck squamous cell carcinoma.
The trial is investigating HUMAN IGG1 HEXAVALENT ANTIBODY AGAINST TNFRSF4 as part of a comparison against placebo when added to pembrolizumab. The brief summary says the study is comparing INBRX-106 plus pembrolizumab versus pembrolizumab for efficacy, meaning how well the treatment works.
Who is being studied
The target population is people with recurrent or metastatic head and neck squamous cell carcinoma. Recurrent means the cancer has come back, and metastatic means it has spread to other parts of the body.
The study also focuses on patients in the first-line setting, which means this is the first treatment used for the current cancer situation. Another key entry requirement in the title is PD-L1 CPS ≥20, which means the study is looking at patients whose tumor-related PD-L1 score is 20 or higher.
Study design and treatment groups
This is a randomized study, so participants are assigned by chance to different treatment groups. Randomization helps make the groups more similar so the results are easier to compare.
The intervention list shows three study-related treatments: commercially available sterile saline solution used as placebo, KEYTRUDA (pembrolizumab), and HUMAN IGG1 HEXAVALENT ANTIBODY AGAINST TNFRSF4 listed as INBRX-106. The source also lists INBRX-106 at 0.1 mg/kg by intravenous infusion, which means it is given into a vein.
The study title and summary show that the main comparison is HUMAN IGG1 HEXAVALENT ANTIBODY AGAINST TNFRSF4 plus pembrolizumab versus pembrolizumab alone with placebo.
What the trial measures
The main outcome measures are overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). These are standard cancer trial endpoints, meaning the main results the researchers want to measure.
ORR is defined in the source as the proportion of patients with a complete response or partial response on 2 consecutive occasions at least 4 weeks apart, using RECIST v1.1 criteria. A complete response means no visible tumor on scans, while a partial response means the tumor has shrunk but not disappeared.
PFS is the time from randomization to disease progression or death from any cause, whichever happens first. OS is the time from randomization to death from any cause.
Trial status and size
The trial status is listed as Authorised. This means the study has been approved to proceed in the source registry.
The planned enrollment is 410 participants. This number gives an idea of the study size and how many people researchers hope to include.